vs
ASTROTECH Corp（ASTC）与Avantor, Inc.（AVTR）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是ASTROTECH Corp的11240.5倍（$1.7B vs $148.0K）。Avantor, Inc.净利率更高（3.1% vs -2653.4%，领先2656.5%）。Avantor, Inc.同比增速更快（-1.4% vs -43.3%）。Avantor, Inc.自由现金流更多（$117.2M vs $-4.0M）。过去两年ASTROTECH Corp的营收复合增速更高（72.0% vs -0.5%）
航天科技公司（原名Spacehab Inc.）是一家总部位于美国得克萨斯州奥斯汀的科技孵化企业。该公司整合内部、研究机构、政府实验室及高校的技术资源，投资、孵化并退出初创企业，旗下子公司还为美国航空航天局、美国国防部、各国航天机构及全球商业客户提供商业化产品与服务。
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
ASTC vs AVTR — 直观对比
营收规模更大
AVTR
是对方的11240.5倍
$148.0K
营收增速更快
AVTR
高出41.9%
-43.3%
净利率更高
AVTR
高出2656.5%
-2653.4%
自由现金流更多
AVTR
多$121.2M
$-4.0M
两年增速更快
ASTC
近两年复合增速
-0.5%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $148.0K | $1.7B |
| 净利润 | $-3.9M | $52.4M |
| 毛利率 | 5.4% | 31.5% |
| 营业利润率 | -2635.8% | 7.6% |
| 净利率 | -2653.4% | 3.1% |
| 营收同比 | -43.3% | -1.4% |
| 净利润同比 | 2.0% | -89.5% |
| 每股收益（稀释后） | — | $0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTCAVTR
| Q4 25 | $148.0K | $1.7B | ||
| Q3 25 | $297.0K | $1.6B | ||
| Q2 25 | $220.0K | $1.7B | ||
| Q1 25 | $534.0K | $1.6B | ||
| Q4 24 | $261.0K | $1.7B | ||
| Q3 24 | $34.0K | $1.7B | ||
| Q2 24 | $74.0K | $1.7B | ||
| Q1 24 | $50.0K | $1.7B |
净利润ASTCAVTR
| Q4 25 | $-3.9M | $52.4M | ||
| Q3 25 | $-3.5M | $-711.8M | ||
| Q2 25 | $-2.9M | $64.7M | ||
| Q1 25 | $-3.6M | $64.5M | ||
| Q4 24 | $-4.0M | $500.4M | ||
| Q3 24 | $-3.3M | $57.8M | ||
| Q2 24 | $-3.0M | $92.9M | ||
| Q1 24 | $-3.2M | $60.4M |
毛利率ASTCAVTR
| Q4 25 | 5.4% | 31.5% | ||
| Q3 25 | 63.3% | 32.4% | ||
| Q2 25 | 33.6% | 32.9% | ||
| Q1 25 | 44.4% | 33.8% | ||
| Q4 24 | 59.4% | 33.4% | ||
| Q3 24 | 26.5% | 32.9% | ||
| Q2 24 | 37.8% | 34.1% | ||
| Q1 24 | 16.0% | 34.0% |
营业利润率ASTCAVTR
| Q4 25 | -2635.8% | 7.6% | ||
| Q3 25 | -1190.6% | -40.0% | ||
| Q2 25 | -1326.4% | 7.7% | ||
| Q1 25 | -724.2% | 9.3% | ||
| Q4 24 | -1655.6% | 37.8% | ||
| Q3 24 | -10670.6% | 7.3% | ||
| Q2 24 | -4518.9% | 10.3% | ||
| Q1 24 | -7066.0% | 8.7% |
净利率ASTCAVTR
| Q4 25 | -2653.4% | 3.1% | ||
| Q3 25 | -1166.7% | -43.8% | ||
| Q2 25 | -1331.8% | 3.8% | ||
| Q1 25 | -680.3% | 4.1% | ||
| Q4 24 | -1536.0% | 29.7% | ||
| Q3 24 | -9641.2% | 3.4% | ||
| Q2 24 | -3998.6% | 5.5% | ||
| Q1 24 | -6308.0% | 3.6% |
每股收益（稀释后）ASTCAVTR
| Q4 25 | — | $0.08 | ||
| Q3 25 | — | $-1.04 | ||
| Q2 25 | — | $0.09 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.73 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $0.14 | ||
| Q1 24 | — | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.0M | $365.4M |
| 总债务越低越好 | — | $3.9B |
| 股东权益账面价值 | $15.5M | $5.6B |
| 总资产 | $19.7M | $11.8B |
| 负债/权益比越低杠杆越低 | — | 0.71× |
8季度趋势，按日历期对齐
现金及短期投资ASTCAVTR
| Q4 25 | $7.0M | $365.4M | ||
| Q3 25 | $11.3M | $251.9M | ||
| Q2 25 | $15.1M | $449.4M | ||
| Q1 25 | $18.1M | $315.7M | ||
| Q4 24 | $21.5M | $261.9M | ||
| Q3 24 | $21.8M | $285.3M | ||
| Q2 24 | $42.9M | $272.6M | ||
| Q1 24 | $52.4M | $234.9M |
总债务ASTCAVTR
| Q4 25 | — | $3.9B | ||
| Q3 25 | — | $3.9B | ||
| Q2 25 | — | $4.2B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.9B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $5.3B |
股东权益ASTCAVTR
| Q4 25 | $15.5M | $5.6B | ||
| Q3 25 | $19.1M | $5.6B | ||
| Q2 25 | $22.1M | $6.3B | ||
| Q1 25 | $24.8M | $6.1B | ||
| Q4 24 | $28.1M | $6.0B | ||
| Q3 24 | $32.1M | $5.6B | ||
| Q2 24 | $34.8M | $5.4B | ||
| Q1 24 | $37.6M | $5.3B |
总资产ASTCAVTR
| Q4 25 | $19.7M | $11.8B | ||
| Q3 25 | $23.2M | $11.7B | ||
| Q2 25 | $27.0M | $12.8B | ||
| Q1 25 | $27.5M | $12.3B | ||
| Q4 24 | $31.0M | $12.1B | ||
| Q3 24 | $34.4M | $12.8B | ||
| Q2 24 | $37.6M | $12.7B | ||
| Q1 24 | $40.2M | $12.8B |
负债/权益比ASTCAVTR
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.67× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.94× | ||
| Q1 24 | — | 1.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $152.7M |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $117.2M |
| 自由现金流率自由现金流/营收 | -2671.6% | 7.0% |
| 资本支出强度资本支出/营收 | 277.7% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 2.91× |
| 过去12个月自由现金流最近4个季度 | $-14.9M | $495.0M |
8季度趋势，按日历期对齐
经营现金流ASTCAVTR
| Q4 25 | $-3.5M | $152.7M | ||
| Q3 25 | $-3.9M | $207.4M | ||
| Q2 25 | $-2.4M | $154.4M | ||
| Q1 25 | $-3.9M | $109.3M | ||
| Q4 24 | $-3.0M | $173.3M | ||
| Q3 24 | $-3.7M | $244.8M | ||
| Q2 24 | $-2.5M | $281.1M | ||
| Q1 24 | $-2.3M | $141.6M |
自由现金流ASTCAVTR
| Q4 25 | $-4.0M | $117.2M | ||
| Q3 25 | $-4.4M | $171.7M | ||
| Q2 25 | $-2.7M | $124.8M | ||
| Q1 25 | $-3.9M | $81.3M | ||
| Q4 24 | $-3.4M | $145.8M | ||
| Q3 24 | $-3.9M | $204.0M | ||
| Q2 24 | $-2.8M | $235.3M | ||
| Q1 24 | $-2.5M | $106.9M |
自由现金流率ASTCAVTR
| Q4 25 | -2671.6% | 7.0% | ||
| Q3 25 | -1476.1% | 10.6% | ||
| Q2 25 | -1231.4% | 7.4% | ||
| Q1 25 | -728.1% | 5.1% | ||
| Q4 24 | -1288.5% | 8.6% | ||
| Q3 24 | -11408.8% | 11.9% | ||
| Q2 24 | -3728.4% | 13.8% | ||
| Q1 24 | -5036.0% | 6.4% |
资本支出强度ASTCAVTR
| Q4 25 | 277.7% | 2.1% | ||
| Q3 25 | 150.8% | 2.2% | ||
| Q2 25 | 158.2% | 1.8% | ||
| Q1 25 | 5.1% | 1.8% | ||
| Q4 24 | 122.2% | 1.6% | ||
| Q3 24 | 567.6% | 2.4% | ||
| Q2 24 | 305.4% | 2.7% | ||
| Q1 24 | 352.0% | 2.1% |
现金转化率ASTCAVTR
| Q4 25 | — | 2.91× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 1.69× | ||
| Q4 24 | — | 0.35× | ||
| Q3 24 | — | 4.24× | ||
| Q2 24 | — | 3.03× | ||
| Q1 24 | — | 2.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTC
暂无分部数据
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
